Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Etidron - Etidronate disodium

Di-Na salt [7414-83-7]. Calcimux. Didronel. Difosfen. Diphos. Diphosphonat. Etidon. HEDSPA. Sodium etidronate. Etidronate disodium, USAN The name Diphos is also used for 1,2-Bis(diphenylphosphino)ethane, B-00338. Used in dentifrices. [Pg.552]

Didromycin Dihydrostreptomycin sulfate Didronel Etidronate disodium Didrothenat Dihydrostreptomycin sulfate Diempax Diazepam Diepin -Medazepam... [Pg.1692]

The mechanism of action of etidronate disodium is most likely related to... [Pg.238]

Bisphosphonates alendronate sodium clodronate disodium etidronate disodium pamidronate disodium risedronate sodium zoledronic acid... [Pg.606]

Contraindications Known hypersensitivity to Etidronate disodium Clinically overt osteomalacia CJ (Z) fO c > o nj U... [Pg.87]

They were randomized to etidronate disodium 200 mg/day for 2 weeks plus calcium lactate 3.0 g/day and alfacalcidol 0.75 micrograms/day) or control (calcium lactate 3.0 g and alfacalcidol 0.75 micrograms/day). Bone mineral density in the lumbar spine and the rate of new vertebral fractures at 48 and 144 weeks were evaluated. With etidronate the mean lumbar spine bone mineral density increased by 3.7% and 4.8% at 48 and 144 weeks respectively. In the control group, the mean lumbar spine bone mineral density increased by 1.5% and 0.4% at 48 and 144 weeks respectively. Of three subgroups, men, premenopausal women, and postmenopausal women, the postmenopausal women had the greatest benefit. Two control patients had new vertebral fractures, whereas there were no fractures with etidronate. [Pg.31]

Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SRTauer K, Neidhart J, Mallette LE, Siegel R, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992 10 ... [Pg.563]

Fiores JF, Singer FR, Rude RK. Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercaicemia of maiignant disease. A dose-ranging piiot study. Miner Eiectroiyte Metab 1991 17 390-395. [Pg.565]

Calcitonin is used in the treatment of Paget s disease (osteitis deformans), a chronic disorder characterized by increased bone remodeling, normocalcemia and normophosphatemia, frequent episodes of hypercalciuria leading to stone formation, and elevation of serum alkaline phosphatase and urinary hydroxyproline levels. The disease does not appear to be primarily a derangement of calcium metabolism. Calcitonin reduces the levels of serum alkaline phosphatase and urinary hydroxyproline, and may relieve other symptoms of the disease as well. Diphosphonates, especially etidronate disodium, also reduce bone resorption in this disease. Various cancers are accompanied by hypercalcemia and may respond to treatment with calcitonin. [Pg.888]

See other pages where Etidron - Etidronate disodium is mentioned: [Pg.1698]    [Pg.1698]    [Pg.1698]    [Pg.600]    [Pg.601]    [Pg.1609]    [Pg.1692]    [Pg.1692]    [Pg.1692]    [Pg.1698]    [Pg.262]    [Pg.355]    [Pg.46]    [Pg.159]    [Pg.477]    [Pg.83]    [Pg.87]    [Pg.45]    [Pg.159]    [Pg.159]    [Pg.1518]    [Pg.1518]    [Pg.1519]    [Pg.588]    [Pg.754]    [Pg.505]    [Pg.116]    [Pg.281]   


SEARCH



Didronel - Etidronate disodium

Disodium

Etidronate disodium

Etidronate disodium mechanism of action

© 2024 chempedia.info